Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 17/20 | 0.82 |
| ▸ | KLK1 | P06870 | 3/20 | 0.82 |
| ▸ | F2 | P00734 | 7/20 | 0.71 |
| ▸ | F10 | P00742 | 6/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14688470 | 0.97 | KLKB1 (0.80) | KLKB1KLK1F2F10LMNA | |
| SCHEMBL14833337 | 0.91 | KLKB1 (1.00) | KLKB1KLK1F2F10 | |
| SCHEMBL2555712 | 0.90 | KLKB1 (0.76) | KLKB1KLK1F2F10 | |
| SCHEMBL14688736 | 0.90 | KLKB1 (0.76) | KLKB1KLK1F2F10 | |
| SCHEMBL2547690 | 0.89 | KLKB1 (0.87) | KLKB1KLK1F2F10 | |
| SCHEMBL14845921 | 0.87 | KLKB1 (1.00) | KLKB1KLK1F2F10MAPT | |
| SCHEMBL2557181 | 0.86 | MAPT (0.78) | KLKB1KLK1F2LMNAMAPT | |
| SCHEMBL14688600 | 0.86 | KLKB1 (0.91) | KLKB1KLK1F2F10 | |
| SCHEMBL14688741 | 0.85 | KLKB1 (0.85) | KLKB1KLK1F2F10 | |
| SCHEMBL14688287 | 0.85 | KLKB1 (0.89) | KLKB1KLK1F2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963440-B2 | Multisubstituted aromatic compounds as inhibitors of thrombin | VERSEON CORPORATION (US) | 2018-05-08 | — | — | US | disclosed |
| US-9533967-B2 | Multisubstituted aromatic compounds as inhibitors of thrombin | VERSEON CORPORATION (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160136177-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | VERSEON INTERNATIONAL CORPORATION | 2016-05-19 | — | — | US | disclosed |
| US-20160122333-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | VERSEON INTERNATIONAL CORPORATION | 2016-05-05 | — | — | US | disclosed |
| EP-2560966-A2 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | Verseon Corporation (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20130040950-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | VERSEON CORPORATION (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2011126903-A2 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | VERSEON, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122333-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | TFPI, PLAT, SERPINC1 | KLKB1 148/4885KLK1 282/4885F2 4/4885 |
| US-20160136177-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | TFPI, PLAT, SERPINC1 | KLKB1 148/4885KLK1 282/4885F2 4/4885 |
| US-20130040950-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | TFPI, PLAT, SERPINC1 | KLKB1 148/4885KLK1 282/4885F2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.